Atrium Therapeutics, Inc. share price logo

Atrium Therapeutics, Inc.

NASDAQ: RNA

$7.93

-0.06

(-0.75%)

as on

Atrium Therapeutics, Inc. Stock Performance

as on October 8, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $7.94
    $8.13
    downward going graph

    -0.13%

    Downside

    2.52%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $7.63
    $73.06
    downward going graph

    3.78%

    Downside

    821.31%

    Upside

    downward going graph

Atrium Therapeutics, Inc. share price movements today

Previous Close
$7.99
Open
$7.95
Volume
182.7K
Market Cap
$136.7M
Day's Low - High
$7.94 - $8.13
52 Week Low - High
$7.63 - $73.06

Atrium Therapeutics, Inc. Historical Returns

1 Month Return
-30.13 %
3 Month Return
-40.69 %
1 Year Return
-83.57 %
3 Year Return
+ 28.11 %
5 Year Return
-65.42 %

Atrium Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Atrium Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$136.7M

EPS (TTM)

-5.12

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.08

Industry PE ratio

-3.09

PEG Ratio

0.03

EBITDA

-260.1M

Revenue (TTM)

36.0M

Profit Margin

97.90%

Return On Equity TTM

-42.90%

Atrium Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Atrium Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$136.7M-65.42%-2.0897.90%0.00%
Neutral$74.8B-35.56%-23.49-12.57%0.00%
StrongBuy$127.3B182.58%29.0086.04%0.00%
Buy$74.8B34.93%17.6484.86%0.50%

Stock Returns calculator for Atrium Therapeutics, Inc. Stock including INR - Dollar returns

The Atrium Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Atrium Therapeutics, Inc. investment value today

Current value as on today

₹17,917

Returns

-₹82,083

(-82.08%)

Returns from Atrium Therapeutics, Inc. Stock

-₹83,568 (-83.57%)

Dollar Impact

₹1,485 (+1.48%)

Analyst Recommendation on Atrium Therapeutics, Inc. Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Atrium Therapeutics, Inc.. Average target price of $25

Atrium Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Atrium Therapeutics, Inc..

What analysts predicted

68.28%UPSIDE

Target Price

$25

Current Price

$7.93

Analyzed by

3 Analysts

High

$25

Target

$25.00

Low

$25

Atrium Therapeutics, Inc. target price $25, a slight upside of 68.28% compared to current price of $7.93. According to 3 analysts rating.

Indian Investors' Interest in Atrium Therapeutics, Inc. Stock

Search interest for Atrium Therapeutics, Inc. Stock has increased by 31% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:31% versus previous 30 day period

Atrium Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
3
2
2
2
1
3
12
0
19
3
Gross Profit
2
1
2
2
1
-134
12
0
19
2
Operating Income
-77
-82
-98
-120
-131
-171
-188
-48
-17
-22
EBITDA
-76
-81
-97
-120
-130
-170
-173
-47
-16
-22
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
1
0
0
0
Income Before Tax
-68
-70
-80
-102
-115
-157
-174
-48
-16
-20
Income Tax Expense
-
-
-
-
-
-
-
0
-
-
Net Income
-68
-70
-80
-102
-115
-157
-174
-48
-16
-20
Net Profit Margin
81.91%
66.41%
100.00%
100.00%
100.00%
-3490.46%
0.00%
100.00%
99.23%
88.58%

Atrium Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
2
6
9
9
9
10
18
Gross Profit
-8
2
-30
-91
7
7
10
18
Operating Income
-10
-17
-44
-118
-178
-235
-378
-76
EBITDA
-10
-16
-43
-117
-177
-233
-376
-76
Interest Expense
0
7
0
-
-
-
-
-
Depreciation
0
0
0
0
1
2
2
0
Income Before Tax
-11
-24
-44
-118
-173
-212
-322
-76
Income Tax Expense
0
-
-
-
-
-
-
0
Net Income
-11
-24
-44
-118
-173
-212
-322
-76
Net Profit Margin
-2125.86%
100.00%
-454.03%
-984.95%
84.96%
78.02%
100.00%
100.00%

Atrium Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-68
-70
-80
-102
-115
-157
-174
-29
-16
-20
Operating Cash Flow
-70
-65
-65
-99
-124
-199
-156
-19
-31
-3
Investing Cash Flow
-32
-274
-482
-64
157
185
-587
0
-2
-191
Financing Cash Flow
389
446
342
13
1
3
850
20
301
-
Change in Cash
286
106
-205
-150
34
-10
106
-
267
-195

Atrium Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-11
-24
-44
-118
-173
-212
-322
-49
Operating Cash Flow
-9
2
-37
-94
-136
-119
-300
-41
Investing Cash Flow
0
0
-7
-82
-189
-130
-854
-1
Financing Cash Flow
5
89
272
176
346
93
1,192
42
Change in Cash
-4
91
227
-1
19
-155
37
-

Global Institutional Holdings in Atrium Therapeutics, Inc.

Check out the Institutions with significant holdings in Atrium Therapeutics, Inc..

Funds
Holdings
Peter Kolchinsky
5.05%
Vanguard
4.76%
iShares
3.44%
Andrew J.M. Spokes
2.04%
Bruce Winson
0.73%

Atrium Therapeutics, Inc. News & Key Events

    Insights on Atrium Therapeutics, Inc.

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Moderna, Inc. Common Stock has given 89.1% return, outperforming this stock by 61.0%

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Moderna, Inc. Common Stock has given 603.7% return, outperforming this stock by 687.3%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, -16.63M → -20.18M (in $), with an average decrease of 21.4% per quarter

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 19.63M → 3.00M (in $), with an average decrease of 84.7% per quarter

    • imgNEGATIVE IMPACT

      Price Dip

      img

      In the last 1 month, RNA stock has moved down by -30.1%

    About Atrium Therapeutics, Inc.

    Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
    OrganisationAtrium Therapeutics, Inc.
    Headquarters10578 Science Center Drive, San Diego, CA, 92121, US
    IndustryBiotechnology
    CEOKathleen Gallagher

    Key Management of Atrium Therapeutics, Inc.

    Name

    Title

    Ms. Kathleen P. Gallagher

    President, CEO & Director

    Mr. Brendan Winslow

    Chief Financial Officer

    Dr. Husam Younis Ph.D., Pharm.D.

    Chief Scientific Officer

    Ms. Stephanie Kenney

    Chief Corporate Affairs Officer

    Dr. Steven George Hughes M.B.A., M.D.

    Chief Medical Officer

    Ms. Rocio Martin Hoyos

    Chief Strategy Officer

    FAQs

    What is Atrium Therapeutics, Inc. share price today?

    Atrium Therapeutics, Inc. share price today is $7.93 as on at the close of the market. Atrium Therapeutics, Inc. share today touched a day high of $8.13 and a low of $7.94.

    What is the 52 week high and 52 week low for Atrium Therapeutics, Inc. share?

    Atrium Therapeutics, Inc. share touched a 52 week high of $73.06 on and a 52 week low of $7.63 on . Atrium Therapeutics, Inc. stock price today i.e. is closed at $7.93,which is 89.15% down from its 52 week high and 3.93% up from its 52 week low.

    What is Atrium Therapeutics, Inc.'s market capitalisation today?

    Atrium Therapeutics, Inc. market capitalisation is $0.00T as on .

    How to invest in Atrium Therapeutics, Inc. Stock (RNA) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Atrium Therapeutics, Inc. on INDmoney app. Click on Buy button.

    What is the minimum amount required to buy Atrium Therapeutics, Inc. Stock (RNA) from India?

    Indian investors can start investing in Atrium Therapeutics, Inc. (RNA) shares with as little as ₹96.779998779297 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹967.80 in Atrium Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Atrium Therapeutics, Inc. share’s latest price of $7.93 as on October 8, 2026 at 8:45 am IST, you will get 1.2610 shares of Atrium Therapeutics, Inc.. Learn more about fractional shares .

    What are the returns that Atrium Therapeutics, Inc. has given to Indian investors in the last 5 years?

    Atrium Therapeutics, Inc. stock has given -65.42% share price returns and 28.18% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?